Abstract
Background CYP2C19 loss-of-function (LOF) alleles decrease the antiplatelet effect of clopidogrel following percutaneous coronary intervention (PCI) in patients presenting with acute coronary syndrome (ACS). The impact of genotype in stable ischemic heart disease (SIHD) is unclear.
Objectives Determine the association of CYP2C19 genotype with major adverse cardiac events (MACE) after PCI for ACS or SIHD.
Methods Million Veterans Program (MVP) participants age <65 years with a PCI documented in the VA Clinical Assessment, Reporting and Tracking (CART) Program between 1/1/2009 to 9/30/2017, treated with clopidogrel were included. Time to MACE defined as the composite of all-cause death, stroke or myocardial infarction within 12 months following PCI.
Results Among 4,461 Veterans (mean age 59.1 ± 5.1 years, 18% Black); 44% had ACS, 56% had SIHD and 29% carried a CYP2C19 LOF allele. 301 patients (6.7%) experienced MACE while being treated with clopidogrel, 155 (7.9%) in the ACS group and 146 (5.9%) in the SIHD group. Overall, MACE was not significantly different between LOF carriers vs. noncarriers (adjusted hazard ratio [HR] 1.18, confidence interval [95%CI] 0.97-1.45, p=0.096). Among patients presenting with ACS, MACE risk in LOF carriers versus non-carriers was numerically higher (HR 1.30, 95%CI 0.98-1.73, p=0.067). There was no difference in MACE risk in patients with SIHD (HR 1.09, 95%CI 0.82-1.44; p=0.565).
Conclusions CYP2C19 LOF carriers presenting with ACS treated with clopidogrel following PCI experienced a numerically greater elevated risk of MACE events. CYP2C19 LOF genotype is not associated with MACE among patients presenting with SIHD.
Competing Interest Statement
JAL and SLD report grants from Alnylam Pharmaceuticals, Inc, grants from Astellas Pharma, Inc, grants from AstraZeneca Pharmaceuticals LP, grants from Biodesix, grants from Boehringer Ingelheim International GmbH, grants from Celgene Corporation, grants from Eli Lilly and Company, grants from Genentech Inc., grants from Gilead Sciences Inc., grants from GlaxoSmithKline PLC, grants from Innocrin Pharmaceuticals Inc., grants from IQVIA Inc., grants from Janssen Pharmaceuticals, Inc., grants from Kantar Health, grants from MDxHealth, grants from Merck & Co., Inc., grants from Myriad Genetic Laboratories, Inc., grants from Novartis International AG, grants from Parexel International Corporation through the University of Utah or Western Institute for Veteran Research outside the submitted work. TMM is an advisor for Myia Labs, for which his employer is receiving equity compensation in the company. SMD receives research support to the University of Pennsylvania from RenalytixAI and Novo Nordisk (in-kind), as well as personal fees from Calico Labs, all outside the current work. JG reports serving on advisory boards and receiving research funding to the institution from Abiomed, Boston Scientific, Abbott Vascular, Recor Medical, Inari Medical, and Astra Zeneca. JG reports equity interest in Endovasular Engineering.
Funding Statement
Funding for MVP003 was provided by I01-BX003362 (K.M.C., P.S.T.). This work was supported using resources and facilities of the Department of Veterans Affairs (VA) Informatics and Computing Infrastructure (VINCI), VA HSR RES 13-457. SMD is supported by IK2-CX001780. ST is supported by K23HL143161
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The MVP received ethical and study protocol approval by the Veterans Affairs Central Institutional Review Board. Informed consent has been obtained from all participants. Each additional study was also approved by the local institutional review board. This project was also approved by the MVP Publication and Presentation Committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All relevant data are available in the main paper and supplemental data. Individual data cannot be shared publicly according to the Data Access Policy of the Million Veteran Program in the VA Office of R&D in Veterans Health Administration.
Abbreviation list
- CART
- Clinical Assessment, Reporting, and Tracking database
- CYP2C19
- Cytochrome P450 2C19
- BARC
- Bleeding Academic Research Consortium
- LOF
- Loss of function
- MACE
- Major adverse cardiac events
- MVP
- Million Veteran Program
- PCI
- Percutaneous coronary intervention
- SIHD
- Stable ischemic heart disease
- STEMI
- ST-segment elevation myocardial infarction
